These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11255447)

  • 1. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease.
    Seshadri S; Zornberg GL; Derby LE; Myers MW; Jick H; Drachman DA
    Arch Neurol; 2001 Mar; 58(3):435-40. PubMed ID: 11255447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus.
    Xu Y; Lin J; Wang S; Xiong J; Zhu Q
    Kaohsiung J Med Sci; 2014 Jul; 30(7):350-61. PubMed ID: 24924841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen replacement therapy and risk of Alzheimer disease.
    Paganini-Hill A; Henderson VW
    Arch Intern Med; 1996 Oct; 156(19):2213-7. PubMed ID: 8885820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging.
    Kawas C; Resnick S; Morrison A; Brookmeyer R; Corrada M; Zonderman A; Bacal C; Lingle DD; Metter E
    Neurology; 1997 Jun; 48(6):1517-21. PubMed ID: 9191758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
    Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Weiss NS; Larson EB; Rosendaal FR; Psaty BM
    JAMA; 2004 Oct; 292(13):1581-7. PubMed ID: 15467060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration.
    Bergendal A; Kieler H; Sundström A; Hirschberg AL; Kocoska-Maras L
    Menopause; 2016 Jun; 23(6):593-9. PubMed ID: 27023862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
    Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
    JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women.
    Psaty BM; Heckbert SR; Atkins D; Lemaitre R; Koepsell TD; Wahl PW; Siscovick DS; Wagner EH
    Arch Intern Med; 1994 Jun; 154(12):1333-9. PubMed ID: 8002685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen replacement therapy in the elderly.
    Paganini-Hill A
    Zentralbl Gynakol; 1996; 118(5):255-61. PubMed ID: 8701621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study.
    Imtiaz B; Taipale H; Tanskanen A; Tiihonen M; Kivipelto M; Heikkinen AM; Tiihonen J; Soininen H; Hartikainen S; Tolppanen AM
    Maturitas; 2017 Apr; 98():7-13. PubMed ID: 28274328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
    Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
    Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of hormone therapy and incident gout: population-based case-control study.
    Bruderer SG; Bodmer M; Jick SS; Meier CR
    Menopause; 2015 Dec; 22(12):1335-42. PubMed ID: 25968834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
    Speroff L
    Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
    JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risks and benefits of estrogen replacement therapy: Leisure World.
    Paganini-Hill A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 1():54-62. PubMed ID: 7581589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.